Clinical Internal Dosimetry and Biodistribution of 177Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma

CONCLUSIONS: The results of our study demonstrated expected and favorable biodistribution and dosimetry with 177Lu-DOTA-trastuzumab in HER2-positive breast carcinoma patients. We noticed the mean absorbed dose to the normal organs within the limits of maximum tolerable dose, and also tumor dose was higher than the normal liver dose. Therefore, we conclude that 177Lu-DOTA-trastuzumab radioimmunotherapy is feasible and a safe treatment option for treating HER2-positive breast carcinoma patients.PMID:38350067 | DOI:10.1097/RLU.0000000000005067

Source: Clinical Breast Cancer - February 13, 2024 Category: Cancer & Oncology Authors: Yoga S Narwadkar Rahul V Parghane Sudeep Sahu Sangita Lad Kamal Deep Gaurav Wanage Tejal Suralkar Sharmila Banerjee Sudeep Gupta Sandip Basu Rajendra A Badwe Source Type: research